Cullinan Therapeutics (CGEM) Change in Accured Expenses (2020 - 2023)
Historic Change in Accured Expenses for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to $5.1 million.
- Cullinan Therapeutics' Change in Accured Expenses rose 21977.26% to $5.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $10.1 million, marking a year-over-year increase of 1782.49%. This contributed to the annual value of $2.9 million for FY2024, which is 7120.55% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Change in Accured Expenses of $5.1 million as of Q4 2023, which was up 21977.26% from $5.2 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Change in Accured Expenses registered a high of $5.2 million during Q3 2023, and its lowest value of -$2.8 million during Q2 2023.
- Over the past 4 years, Cullinan Therapeutics' median Change in Accured Expenses value was $1.6 million (recorded in 2021), while the average stood at $1.6 million.
- Data for Cullinan Therapeutics' Change in Accured Expenses shows a peak YoY increase of 1330476.19% (in 2021) and a maximum YoY decrease of 64511.63% (in 2021) over the last 5 years.
- Cullinan Therapeutics' Change in Accured Expenses (Quarter) stood at -$21000.0 in 2020, then surged by 13304.76% to $2.8 million in 2021, then tumbled by 42.91% to $1.6 million in 2022, then surged by 219.77% to $5.1 million in 2023.
- Its last three reported values are $5.1 million in Q4 2023, $5.2 million for Q3 2023, and -$2.8 million during Q2 2023.